AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34974959 — intervention group
Group type: COMPARATOR
Intervention: Modified Risdon approach
Number of subjects: 21
Study 34697586 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive news about COVID-19
Number of subjects: 717
Study 34697586 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative news about COVID-19
Number of subjects: 717
Study 34697586 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation pause after news
Number of subjects: 717
Study 34697586 — intervention group
Group type: EXPERIMENTAL
Intervention: Practicing physical activity, meditation/yoga
Number of subjects: 717
Study 32520984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 415
Study 32520984 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 415
Study 32520984 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Training (AT+RT)
Number of subjects: 415
Study 32520984 — intervention group
Group type: COMPARATOR
Intervention: Control group (lectures about health promotion)
Number of subjects: 415
Study 35835311 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 66
Study 35835311 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 66
Study 33054488 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Game Design (CBGD) based mobile game
Number of subjects: 140
Study 33054488 — intervention group
Group type: COMPARATOR
Intervention: Video documentary
Number of subjects: 140
Study 34236253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration hypochlorous acid (HOCl) nasal irrigation
Number of subjects: 139
Study 34236253 — intervention group
Group type: COMPARATOR
Intervention: Normal saline nasal irrigation
Number of subjects: 139
Study 33685434 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF) intervention
Number of subjects: 297
Study 34958142 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day montelukast (Group 2)
Number of subjects: 180
Study 34958142 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day montelukast (Group 3)
Number of subjects: 180
Study 34958142 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (Group 1)
Number of subjects: 180
Study 33789655 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection alone
Number of subjects: 216
Study 33789655 — intervention group
Group type: COMPARATOR
Intervention: Visual inspection combined with radiographic assessment
Number of subjects: 216
Study 35131378 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care (medication therapy management and telephonic follow‐up with visits to family physicians, nurses, and dietitians)
Number of subjects: 264
Study 35131378 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 264
Study 35131378 — intervention group
Group type: COMPARATOR
Intervention: Physician‐centric care
Number of subjects: 264
Study 34656226 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan (70 mg/m2 for 90 min) plus leucovorin (400 mg/m2 for 30 min) and fluorouracil (2400 mg/m2 for 46 h) every 2 weeks
Number of subjects: 174
Study 34656226 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin only every 2 weeks
Number of subjects: 174
Study 34656226 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan plus fluorouracil and leucovorin
Number of subjects: 174
Study 34656226 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 174
Study 33146763 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised screening at 6, 12 or 24 months based on risk levels
Number of subjects: 4534
Study 33146763 — intervention group
Group type: COMPARATOR
Intervention: Annual screening (control group)
Number of subjects: 4534
Study 33146763 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised screening
Number of subjects: 4534
Study 35024794 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally Minimally Invasive Oesophagectomy (TMIE)
Number of subjects: 8640
Study 33247380 — intervention group
Group type: EXPERIMENTAL
Intervention: HCQ and zinc (group I)
Number of subjects: 191
Study 33247380 — intervention group
Group type: COMPARATOR
Intervention: HCQ only (group II)
Number of subjects: 191
Study 36282079 — intervention group
Group type: EXPERIMENTAL
Intervention: CSL112 (2 g and 6 g)
Number of subjects: 63
Study 36282079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 33730345 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (PEEP 10cmH2O and FiO2 0.21) for 40 minutes
Number of subjects: 13
Study 35268057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ca+vitamin D supplements (S)
Number of subjects: 97
Study 35268057 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat dairy foods (D; 4−5 servings/day)
Number of subjects: 97
Study 35268057 — intervention group
Group type: COMPARATOR
Intervention: Control/placebo pills (C)
Number of subjects: 97
Study 34699903 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper Next (GPT)
Number of subjects: 24
Study 34699903 — intervention group
Group type: EXPERIMENTAL
Intervention: One Shape (GOS)
Number of subjects: 24
Study 34699903 — intervention group
Group type: EXPERIMENTAL
Intervention: Wave One Gold (GWO)
Number of subjects: 24
Study 34699903 — intervention group
Group type: EXPERIMENTAL
Intervention: TF Adaptive (GTF)
Number of subjects: 24
Study 34606579 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 10
Study 34606579 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 34980887 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (triple-strain bifidobacterial probiotic)
Number of subjects: 61
Study 34980887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 33855726 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Check‐Up (FCU) Online telehealth intervention
Number of subjects: 111
Study 34425088 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine encounters
Number of subjects: 200
Study 34425088 — intervention group
Group type: COMPARATOR
Intervention: In-person encounters
Number of subjects: 200
Study 34458731 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antimicrobial stewardship (AMS) team intervention (review 48 h post-MET call)
Number of subjects: 90
Study 34458731 — intervention group
Group type: COMPARATOR
Intervention: Standard care (management of antimicrobial therapy by the treating team)
Number of subjects: 90
Study 34458731 — intervention group
Group type: EXPERIMENTAL
Intervention: Early antimicrobial stewardship (AMS) team intervention
Number of subjects: 90
Study 34458731 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 90
Study 33783922 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused-attention meditation training for 3 months
Number of subjects: 0
Study 33783922 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 32131073 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone application‐based exercise program
Number of subjects: 63
Study 32131073 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 63
Study 34713365 — intervention group
Group type: EXPERIMENTAL
Intervention: Membracel® + LED (Photobiomodulation)
Number of subjects: 21
Study 34713365 — intervention group
Group type: COMPARATOR
Intervention: Membracel® (Control)
Number of subjects: 21
Study 32744418 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 12621
Study 32744418 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 12621
Study 32744418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12621
Study 33454989 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (T4) and Thyroid-stimulating hormone (TSH)
Number of subjects: 800
Study 33454989 — intervention group
Group type: EXPERIMENTAL
Intervention: Free T4 (fT4)
Number of subjects: 800
Study 33454989 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroid hormones (fT4 and TSH)
Number of subjects: 800
Study 33454989 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variants influencing fT4 and TSH concentrations
Number of subjects: 800
Study 33454989 — intervention group
Group type: EXPERIMENTAL
Intervention: fT4
Number of subjects: 800
Study 33866004 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan-based regimen
Number of subjects: 897
Study 33866004 — intervention group
Group type: COMPARATOR
Intervention: Non-irinotecan containing regimen
Number of subjects: 897
Study 32096470 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure form of CBD
Number of subjects: 0
Study 32096470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35764263 — intervention group
Group type: EXPERIMENTAL
Intervention: Pm-Pac plus cisplatin
Number of subjects: 448
Study 35764263 — intervention group
Group type: COMPARATOR
Intervention: Sb-Pac plus cisplatin
Number of subjects: 448
Study 33730804 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS group
Number of subjects: 80
Study 32434867 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma neurofilament light chain (pNfL) levels
Number of subjects: 4385
Study 35315076 — intervention group
Group type: EXPERIMENTAL
Intervention: Charge Your Brainzzz intervention
Number of subjects: 972
Study 35315076 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 972
Study 33712267 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Number of subjects: 16446
Study 33712267 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/nab‐paclitaxel (Gem/NabP)
Number of subjects: 16446
Study 33712267 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line therapy with Gem/NabP or FOLFIRINOX
Number of subjects: 16446
Study 32990370 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% aluminum sesquichlorohydrate (AS)
Number of subjects: 20
Study 32990370 — intervention group
Group type: COMPARATOR
Intervention: 20% aluminum chloride (AC)
Number of subjects: 20
Study 35311753 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-incision negative-pressure wound therapy for 5 days
Number of subjects: 60
Study 35311753 — intervention group
Group type: COMPARATOR
Intervention: Regular dressings (Control)
Number of subjects: 60
Study 35311753 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-incision negative-pressure wound therapy
Number of subjects: 60
Study 33244706 — intervention group
Group type: EXPERIMENTAL
Intervention: GuttaCore
Number of subjects: 212
Study 33244706 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 212
Study 33244706 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave condensation
Number of subjects: 212
Study 33244706 — intervention group
Group type: COMPARATOR
Intervention: Single cone with AH plus
Number of subjects: 212
Study 33244706 — intervention group
Group type: COMPARATOR
Intervention: Single cone with BioRoot RCS
Number of subjects: 212
Study 32047245 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g TestimTM gel (containing 50 mg testosterone)
Number of subjects: 96
Study 32047245 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 96
Study 35041624 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting single methane measurement (SMM) ≥10 ppm
Number of subjects: 0
Study 35041624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35041624 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 0
Study 35041624 — intervention group
Group type: EXPERIMENTAL
Intervention: SMM
Number of subjects: 0
Study 32892305 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred music therapy (PMT) which included educational counseling (EC) plus 15, 30-min preferred music sessions (PMS)
Number of subjects: 60
Study 32892305 — intervention group
Group type: COMPARATOR
Intervention: Educational counseling (EC) which included a 1-h individualized instruction
Number of subjects: 60
Study 35771264 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 36
Study 35771264 — intervention group
Group type: COMPARATOR
Intervention: Giotrif®
Number of subjects: 36
Study 34987115 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 57
Study 34987115 — intervention group
Group type: COMPARATOR
Intervention: Active Control (physical exercise and health education)
Number of subjects: 57
Study 36067728 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person counseling
Number of subjects: 961
Study 36067728 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated individualized feedback letters
Number of subjects: 961
Study 36067728 — intervention group
Group type: COMPARATOR
Intervention: Assessment only
Number of subjects: 961
Study 32705913 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile predictive intervention used by Service Coordinators (SCs)
Number of subjects: 420
Study 32705913 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mobile predictive intervention)
Number of subjects: 420
Study 32725584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 25 mg/day
Number of subjects: 0
Study 32725584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg/day
Number of subjects: 0
Study 32725584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32725584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (both doses)
Number of subjects: 0
Study 32725584 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron and Placebo
Number of subjects: 0
Study 36206331 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization to foster care
Number of subjects: 0
Study 36206331 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34288808 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 165
Study 34288808 — intervention group
Group type: COMPARATOR
Intervention: Control (Euthyroid women)
Number of subjects: 165
Study 32733703 — intervention group
Group type: EXPERIMENTAL
Intervention: TBFP1 (based on circumferences)
Number of subjects: 350
Study 32733703 — intervention group
Group type: EXPERIMENTAL
Intervention: TBFP2 (based on skinfold thickness)
Number of subjects: 350
Study 32733703 — intervention group
Group type: EXPERIMENTAL
Intervention: TBFP4 (based on highly significant circumferences and skinfold thickness)
Number of subjects: 350
Study 36069798 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Cognitive Behavioral Therapy (B‐CBT) - 6 sessions of face-to-face CBT alternated with 6-8 web-based CBT self-help modules.
Number of subjects: 76
Study 36069798 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT) - 12 sessions of traditional face-to-face CBT.
Number of subjects: 76
Study 36069798 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended Cognitive Behavioral Therapy (B‐CBT)
Number of subjects: 76
Study 36069798 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face Cognitive Behavioral Therapy (FtF‐CBT)
Number of subjects: 76
Study 34111592 — intervention group
Group type: EXPERIMENTAL
Intervention: Uva ursi (UU) 105 mg 3 × 2 tablets for 5 days
Number of subjects: 398
Study 34111592 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin 3-g single dose
Number of subjects: 398
Study 34111592 — intervention group
Group type: EXPERIMENTAL
Intervention: Uva ursi (UU)
Number of subjects: 398
Study 34111592 — intervention group
Group type: COMPARATOR
Intervention: Fosfomycin
Number of subjects: 398
Study 35301883 — intervention group
Group type: EXPERIMENTAL
Intervention: AD‐MSCs
Number of subjects: 13
Study 35301883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 35301883 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 13
Study 32107269 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 50
Study 32107269 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 33221606 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) group treatment for perinatal depression, 12 sessions
Number of subjects: 49
Study 33221606 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49
Study 32328709 — intervention group
Group type: EXPERIMENTAL
Intervention: Drospirenone-only pill 4 mg
Number of subjects: 0
Study 32328709 — intervention group
Group type: COMPARATOR
Intervention: Desogestrel 0.075 mg
Number of subjects: 0
Study 35210118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal fractional third dose of AZD1222 vaccine (20% of standard dose)
Number of subjects: 125
Study 35210118 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal fractional third dose of AZD1222 vaccine (40% of standard dose)
Number of subjects: 125
Study 35210118 — intervention group
Group type: COMPARATOR
Intervention: Standard intramuscular third dose of AZD1222 vaccine
Number of subjects: 125
Study 33788484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electrical stimulation therapy at Huantiao (GB 30), Futu (ST 32), Zusanli (ST 36), Xuanzhong (GB 39), and Taichong (LR 3), 2 times daily for 7 days.
Number of subjects: 58
Study 33788484 — intervention group
Group type: COMPARATOR
Intervention: Routine basic treatment (Control group).
Number of subjects: 58
Study 33788484 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint electrical stimulation therapy.
Number of subjects: 58
Study 32947572 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-load ballistic resistance training (LL: 6 × 12 × 40% 1RM)
Number of subjects: 15
Study 32947572 — intervention group
Group type: COMPARATOR
Intervention: Heavy-load ballistic resistance training (HL: 6 × 6 × 80% 1RM)
Number of subjects: 15
Study 32947572 — intervention group
Group type: EXPERIMENTAL
Intervention: Light-load ballistic resistance training (LL)
Number of subjects: 15
Study 34534292 — intervention group
Group type: COMPARATOR
Intervention: TS‐161 (15-400 mg single dose)
Number of subjects: 0
Study 34534292 — intervention group
Group type: COMPARATOR
Intervention: TS‐161 (50-150 mg multiple doses over 10 days)
Number of subjects: 0
Study 34534292 — intervention group
Group type: COMPARATOR
Intervention: TS‐161 (100 mg single dose)
Number of subjects: 0
Study 34534292 — intervention group
Group type: COMPARATOR
Intervention: TS‐161
Number of subjects: 0
Study 32771034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nigella sativa oil (MARNYS® Cuminmar) 500 mg softgel capsules, one capsule orally twice daily for 10 days plus standard of care treatment (antipyretic, antitussive)
Number of subjects: 200
Study 32771034 — intervention group
Group type: COMPARATOR
Intervention: Standard of care treatment
Number of subjects: 200
Study 36427258 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum electroacupuncture stimulation (EAS) at scalp acupoints Shenting (GV24) and Touwei (ST8) during fMRI.
Number of subjects: 60
Study 36427258 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture stimulation at acupoints Shenting (GV24) and Touwei (ST8) without EAS during fMRI.
Number of subjects: 60
Study 33958862 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Function Questionnaire (LFQ) followed by pocket spirometry
Number of subjects: 3256
Study 33635779 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice of medication reminder modality (text, email, phone)
Number of subjects: 7522
Study 33635779 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no choice of reminder modality)
Number of subjects: 7522
Study 35452419 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BVZ) plus XELOX chemotherapy with mindfulness-based stress reduction (MBSR) intervention
Number of subjects: 88
Study 35452419 — intervention group
Group type: COMPARATOR
Intervention: XELOX chemotherapy with conventional care
Number of subjects: 88
Study 32949505 — intervention group
Group type: EXPERIMENTAL
Intervention: RIMA vascular device occlusion (verum group)
Number of subjects: 100
Study 32949505 — intervention group
Group type: COMPARATOR
Intervention: RIMA sham procedure (placebo group)
Number of subjects: 100
Study 34739648 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Ischaemic Conditioning (RIC) - four 5-min cycles of inflation (20 mmHg above systolic blood pressure) and deflation of an automated blood pressure cuff placed on the upper arm, applied daily for 2 days.
Number of subjects: 1200
Study 34739648 — intervention group
Group type: COMPARATOR
Intervention: Sham control - similar protocol but with low-pressure inflation of 20 mmHg and deflation, applied daily for 2 days.
Number of subjects: 1200
Study 33955942 — intervention group
Group type: EXPERIMENTAL
Intervention: Yogic pranayama and diaphragmatic breathing exercises (daily for 6 months)
Number of subjects: 90
Study 33955942 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 90
Study 32943015 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-monthly multimodal vascular risk factor intervention jointly delivered by the trial team and General Practitioner (GP)
Number of subjects: 73
Study 32943015 — intervention group
Group type: COMPARATOR
Intervention: Usual care from the GP (Control)
Number of subjects: 73
Study 35850666 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental cord drainage
Number of subjects: 400
Study 35850666 — intervention group
Group type: COMPARATOR
Intervention: No placenta drainage (Control)
Number of subjects: 400
Study 33893865 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment with meibomian gland expression (MGX)
Number of subjects: 64
Study 33893865 — intervention group
Group type: COMPARATOR
Intervention: MGX-alone treatment
Number of subjects: 64
Study 33893865 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser treatment with MGX
Number of subjects: 64
Study 32664084 — intervention group
Group type: EXPERIMENTAL
Intervention: HT083
Number of subjects: 100
Study 32664084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 33755978 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum combined with sodium bicarbonate nursing (experimental group)
Number of subjects: 120
Study 33755978 — intervention group
Group type: COMPARATOR
Intervention: Colostrum (control group I)
Number of subjects: 120